CMS to analyze ESAs in CKD

The Centers for Medicare & Medicaid Services began a national coverage analysis covering the use of erythropoiesis-stimulating agents (ESAs) to treat anemia in chronic kidney disease (CKD) after receiving a request to create a national coverage determination (NCD) for the products. CMS said it is requesting a technology assessment from an outside entity. The agency also is requesting public comments for the next 30 days on the effects of ESAs on health outcomes in CKD patients. The analysis is expected to be completed by next June. ...